Subtopic Deep Dive
Economic Burden of the Opioid Epidemic
Research Guide
What is Economic Burden of the Opioid Epidemic?
Economic Burden of the Opioid Epidemic quantifies healthcare costs, lost productivity, criminal justice expenses, and fiscal impacts attributable to opioid misuse in the context of opioid use disorder treatment.
Studies estimate total U.S. economic costs of opioid misuse exceed hundreds of billions annually (Maclean et al., 2020, 86 citations). Analyses cover prevalence and risk-adjusted costs in populations like Veterans Health Administration patients (Başer et al., 2013, 82 citations). Methodologies include DATCAP and ASI for benefit-cost analysis of addiction treatments (French et al., 2002, 121 citations).
Why It Matters
Cost estimates exceeding $23.4 billion for similar substances like methamphetamine inform opioid policy budgeting (Nicosia et al., 2009, 137 citations). Veterans with diagnosed opioid abuse incur 3-4 times higher healthcare costs than non-abusers, justifying targeted interventions (Başer et al., 2013). Maclean et al. (2020) review shows comprehensive economic data guides resource allocation for prevention, with over 128 daily overdose deaths driving fiscal priorities. French et al. (2002) demonstrate benefit-cost ratios exceeding 12:1 for treatments, supporting public funding.
Key Research Challenges
Heterogeneous Cost Measurement
Varied methodologies like DATCAP yield inconsistent estimates across studies (French et al., 2002). Attribution of societal costs such as lost productivity remains debated. Standardization lacks in opioid-specific analyses (Maclean et al., 2020).
Long-term Fiscal Forecasting
Predicting policy impacts requires modeling uncertain behavioral responses (Hastings et al., 2020). Dynamic costs from chronic use post-acute episodes complicate projections (Thiels et al., 2019). Limited longitudinal data hinders accuracy.
Population-specific Burden Gaps
Veterans show elevated costs, but generalizability to civilians is unclear (Başer et al., 2013). Underserved groups like hospitalized SUD patients lack scaled economic data (Pecoraro et al., 2012). Risk adjustment methods vary, biasing comparisons.
Essential Papers
The individual and societal burden of chronic pain in Europe: the case for strategic prioritisation and action to improve knowledge and availability of appropriate care
Harald Breivik, Elon Eisenberg, Tony O’Brien · 2013 · BMC Public Health · 621 citations
European Pain Federation position paper on appropriate opioid use in chronic pain management
Timothy O’Brien, Lona Louring Christrup, Asbjørn Mohr Drewes et al. · 2016 · European Journal of Pain · 207 citations
Abstract Poorly controlled pain is a global public health issue. The personal, familial and societal costs are immeasurable. Only a minority of European patients have access to a comprehensive spec...
The Economic Cost of Methamphetamine Use in the United States, 2005
Nancy Nicosia, Rosalie Liccardo Pacula, Beau Kilmer et al. · 2009 · RAND Corporation eBooks · 137 citations
This first national estimate of the economic cost of methamphetamine (meth) use in the United States suggests that costs reached $23.4 billion in 2005. The analysis, with a lower-bound estimate of ...
Benefit‐Cost Analysis of Addiction Treatment: Methodological Guidelines and Empirical Application Using the DATCAP and ASI
Michael T. French, Helena J. Salomé, Jody L. Sindelar et al. · 2002 · Health Services Research · 121 citations
Objective. To provide detailed methodological guidelines for using the Drug Abuse Treatment Cost Analysis Program (DATCAP) and Addiction Severity Index (ASI) in a benefit‐cost analysis of addiction...
Chronic use of tramadol after acute pain episode: cohort study
Cornelius A. Thiels, Elizabeth B. Habermann, W. Michael Hooten et al. · 2019 · BMJ · 120 citations
Abstract Objective To determine the risk of prolonged opioid use in patients receiving tramadol compared with other short acting opioids. Design Observational study of administrative claims data. S...
Economic Studies on the Opioid Crisis: A Review
Johanna Catherine Maclean, Justine Mallatt, Christopher J. Ruhm et al. · 2020 · 86 citations
The United States has experienced an unprecedented crisis related to the misuse of and addiction to opioids.As of 2018, 128 Americans die each day of an opioid overdose, and total economic costs as...
Prevalence of Diagnosed Opioid Abuse and its Economic Burden in the Veterans Health Administration
Onur Başer, Lin Xie, Jack Mardekian et al. · 2013 · Pain Practice · 82 citations
Abstract Objective Evaluate prevalence and risk‐adjusted healthcare costs of diagnosed opioid abuse in the national V eterans H ealth A dministration ( VHA ). Costs were compared between patients w...
Reading Guide
Foundational Papers
Start with Breivik et al. (2013, 621 citations) for chronic pain societal burden framing, then French et al. (2002, 121 citations) for DATCAP/ASI addiction cost methods, and Nicosia et al. (2009, 137 citations) for national cost estimation techniques.
Recent Advances
Study Maclean et al. (2020, 86 citations) for opioid crisis review, Hastings et al. (2020, 51 citations) for risk prediction economics, and Thiels et al. (2019, 120 citations) for chronic use cost risks.
Core Methods
Core techniques include DATCAP/ASI benefit-cost analysis (French et al., 2002), risk-adjusted VHA cost modeling (Başer et al., 2013), and machine learning for prescription risk forecasting (Hastings et al., 2020).
How PapersFlow Helps You Research Economic Burden of the Opioid Epidemic
Discover & Search
Research Agent uses searchPapers and exaSearch to find 50+ papers on opioid economic costs, revealing Maclean et al. (2020) as a key review with 86 citations. citationGraph traces impacts from Breivik et al. (2013, 621 citations) to opioid contexts. findSimilarPapers expands from Başer et al. (2013) to VHA cost studies.
Analyze & Verify
Analysis Agent applies readPaperContent to extract cost breakdowns from Nicosia et al. (2009), then runPythonAnalysis with pandas to recompute $23.4 billion meth estimates for opioid scaling. verifyResponse (CoVe) checks claims against French et al. (2002) DATCAP methods; GRADE grading scores evidence as high for benefit-cost ratios.
Synthesize & Write
Synthesis Agent detects gaps in veteran vs. civilian cost data via contradiction flagging across Başer et al. (2013) and Maclean et al. (2020). Writing Agent uses latexEditText and latexSyncCitations to draft cost-effectiveness tables, latexCompile for PDF reports, and exportMermaid for burden visualization diagrams.
Use Cases
"Run cost-benefit simulation for opioid treatment programs using DATCAP data."
Research Agent → searchPapers(DATCAP opioid) → Analysis Agent → runPythonAnalysis(pandas simulation of French et al. 2002 ratios) → outputs CSV of 12:1 benefit-cost projections.
"What are total economic costs of opioid abuse in veterans vs. general population?"
Research Agent → citationGraph(Başer 2013) → Synthesis Agent → gap detection → Writing Agent → latexEditText(draft comparison table) + latexSyncCitations + latexCompile → LaTeX PDF with risk-adjusted cost visuals.
"Find open-source code for opioid prescription risk prediction models."
Research Agent → paperExtractUrls(Hastings 2020) → Code Discovery → paperFindGithubRepo → githubRepoInspect → outputs Python ML code for high-risk forecasting adapted to economic burden analysis.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ opioid cost papers, chaining searchPapers → citationGraph → GRADE grading for structured economic summary report. DeepScan applies 7-step analysis with CoVe checkpoints to verify Başer et al. (2013) VHA costs against Maclean et al. (2020). Theorizer generates fiscal impact theories from French et al. (2002) and Nicosia et al. (2009) data.
Frequently Asked Questions
What is the definition of economic burden in opioid epidemic research?
Economic burden quantifies healthcare, productivity loss, and justice costs from opioid misuse, as modeled in DATCAP frameworks (French et al., 2002).
What methods assess opioid treatment cost-effectiveness?
DATCAP and ASI provide guidelines for benefit-cost analysis, yielding ratios over 12:1 (French et al., 2002, 121 citations).
What are key papers on opioid economic costs?
Maclean et al. (2020, 86 citations) reviews U.S. crisis costs; Başer et al. (2013, 82 citations) quantifies VHA burdens.
What open problems exist in opioid burden studies?
Forecasting policy effects and standardizing veteran-civilian comparisons remain unresolved (Hastings et al., 2020; Maclean et al., 2020).
Research Opioid Use Disorder Treatment with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Economic Burden of the Opioid Epidemic with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Opioid Use Disorder Treatment Research Guide